Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer
{{output}}
Lung cancer is the most common cancer worldwide, with 1.3 million new cases diagnosed every year. Non-small-cell lung carcinoma (NSCLC) has previously had a very poor prognosis with few effective therapies; however, research has identified that it is associate... ...